PPD Dermatology
PPD® Dermatology seeks to discover new drug candidates and evaluate existing candidates across a range of dermatological disorders such as psoriasis, acne and atopic dermatitis. Promising candidates will be fed into our compound partnering program for further development using our extensive preclinical and clinical resources.
The scientific credentials of PPD Dermatology include unique dermal biology resources to screen compounds for their potential to work in topical indications. Researchers use state-of-the-art research and development capability to do the work.
First-Class Team, Broad Research Capabilities
At our 13,000-square-foot lab in Waltham, Mass., PPD Dermatology has an experienced team of professionals with research, preclinical, dermal biology and extensive development expertise. We offer innovative screening and research capabilities that include cell-based systems, human skin explant models, irritation testing, high throughput cytokine analysis and biomarker analysis to model a variety of skin diseases.
Our most advanced compound is a vitamin D receptor modulator being developed for the treatment of psoriasis, atopic dermatitis and acne. It has demonstrated potent anti-proliferative and anti-inflammatory effects with no irritancy in an in vitro model as well as increased potency and duration of action relative to other vitamin D analogs currently on the market.
Johnson & Johnson completes three additional Phase III studies using Priligy® (dapoxetine) for the treatment of premature ejaculation. The new studies increase the number of subjects, providing an expanded safety database and confirmed efficacy.
PPD acquires biotechnology company Magen BioSciences, Inc. The deal expands PPD's compound partnering program into dermatology.
Our e-Newsletter is your source for what is happening at PPD and in the CRO industry.
